-
ASCO Plenary Series | Dr. Ruihua Xu and Dr. Florian Lordick: FRUTIGA Study Offers New Hope for Second-Line Treatment of Advanced Gastric Cancer
The field of second-line treatment for advanced gastric cancer is a current focal point in oncology research. On February 6, 2024, during the ASCO Plenary Series, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center presented findings from the FRUTIGA study (NCT03223376), a phase III trial conducted in China evaluating the efficacy of fruquintinib combined…
-
SIBCS| Dr. Virginia Kaklamani’s Insights on Post-CDK4/6i Management of HR+ Advanced Breast Cancer at MD Anderson
On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this…
-
Treatment Options for MET-Amplified EGFR-Mutated NSCLC Following Third-Generation TKI Resistance
For patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), dual inhibition of EGFR and MET may be the most effective strategy after disease progression on osimertinib, particularly for patients with MET gene amplification (METamp). Dr. Benjamin Besse, Dr. Lodovica Zullo, and Dr. Jordi Remon from the Gustave Roussy Institute analyze therapeutic strategies for METamp-driven…
-
Dr. Benlong Yang: New Frontiers in Breast Reconstruction – Prevention and Management of Implant Complications
Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong…
-
Prof. Xiaohui Zhang’s Team: International First Exploration of JAK1/2 Inhibitor Baricitinib for the Treatment of Adult Primary ITP
Prof. Xiaohui Zhang’s pioneering study marks the first international use of baricitinib for hormone-resistant/relapsed immune thrombocytopenia (ITP). This phase 2 trial with 35 adult patients achieved a 6-month response rate of 57.1% and was well-tolerated, opening new avenues for ITP treatment. The findings were presented at the European Hematology Association and published in the American…
-
Significant Clinical Research at the 2024 International Liver Cancer Association (ILCA) Annual Conference！
From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference…
-
Call for Papers by November 24丨Beijing APASL 2025 Annual Meeting, Inviting Liver Disease Research Experts to Participate
This will be the largest and most prestigious academic gathering in 2025 for liver disease and related fields in the Asia-Pacific region. The conference will cover a broad range of…
-
CSCO 2024 | Dr. Jianming Guo: Combining the Latest Advances to Further Improve Surgical Treatment for Prostate Cancer in China
Surgical treatment is a crucial approach for prostate cancer, with radical prostatectomy being the gold standard. Even for intermediate and advanced prostate cancer, surgery can offer the possibility of clinical cure. For rare subtypes and complex cases, decisions often require multidisciplinary team (MDT) discussions and thorough communication with the patient. During the recent CSCO Annual…
Connecting Medical Expertise through Media